Written in conjunction with Novo Nordisk's Kate Mulroney.
Understanding and quantifying the patient journey is a critical component for life sciences organizations seeking to analyze markets and design effective intervention strategies across the enterprise. While patient journey mapping within a single therapeutic area (TA) is well-established, cardiometabolic diseases present a far more intricate challenge. These conditions are characterized by extensive cross-linkages across TAs, with patients often starting with one condition and eventually progressing to multiple interconnected diseases due to the nature of cardiometabolic disorders.
Patients navigate these complex journeys in diverse ways. So, it is essential to comprehend the pathways that span from disease onset through progression, treatment and monitoring—not only within a single condition but also across interrelated cardiometabolic diseases (for instance diabetes, obesity and atherosclerotic cardiovascular disease [ASCVD]).
With a growing therapeutic pipeline aimed at addressing these conditions, our objective in creating the analysis was to identify and quantify cardiometabolic patient pathways by developing distinct “archetypes.” These archetypes are based on a scalable framework designed to minimize manual intervention and enable the efficient re-creation and adaptation of patient segments for additional indications and populations in the future.
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
